NEURO61

Session information

Print

Neuroscience Frontier Symposium

[NFS-01] Neuroscience Frontier Symposium 01
New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases

Tue. Sep 1, 2020 4:00 PM - 5:30 PM Room 10 (Okayama Prefectural Medical Association 2F miki anniversary Hall)

Chair：TakeshiIwatsubo（The University of Tokyo, Neuropathology）,KenjiroOno（Division of Neurology, Department of Medicine, Showa University School of Medicine）

[NFS-01-1] The pathological link of glia activation with amyloid clearance in Alzheimer disease

○Taisuke Tomita (Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.

[NFS-01-2] Principles of Inflammasome Priming and Inhibition: Implications for Neurodegenerative Disorders

○Giulio M. Pasinetti1,2 (1.Icahn School of Medicine at Mount Sinai, USA, 2.James J Peters Veterans Affairs Medical Center, USA)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.

[NFS-01-3] HMW Aβ oligomers are important targets for disease modifying approach of Alzheimer's disease

○Kenjiro Ono (Division of Neurology, Department of Medicine, School of Medicine, Showa University, Japan)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.